Skip to content

Study · Systematic review · 2017

2 results

Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.

Mannucci E, Monami M

Advances in therapy14 Nov 2016Cited by 29 (Europe PMC)

PMID27844335 (opens in a new tab)PMCIDPMC5216099 (opens in a new tab)DOI10.1007/s12325-016-0432-4 (opens in a new tab)PepBankPUB-27844335
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a randomised trial included in a systematic review of adults with type 2 diabetes, liraglutide reduced MACE risk by 13% versus placebo.

    In plain wordsIn adults with type 2 diabetes, one trial found liraglutide cut major heart events by 13% compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseMajor adverse cardiac events (MACE)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    MACE risk reduction
    13%
    liraglutide vs placebo

    Source sentences

    Summary
    A fifth RCT showed that liraglutide reduced MACE risk by 13% versus placebo.
    1 context sentence
    Summary · context
    The National Institutes of Health Medline database was searched for pooled analyses, meta-analyses, and randomized controlled trials (RCTs) of DPP-4 inhibitors and GLP-1 receptor agonists that included CV endpoints.

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 02HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In adults with type 2 diabetes, exposure to a DPP-4 inhibitor or GLP-1 receptor agonist (pooled class) did not raise the short-term risk of MACE compared with comparator agents.

    In plain wordsIn adults with type 2 diabetes, these drug classes together did not raise short-term major heart event risk compared with other treatments.

    Peptide
    Liraglutide
    Outcome
    No significant changeMACE with pooled DPP-4 inhibitors or GLP-1 receptor agonists
    Study

    n: not reported in source

    Comparator
    Comparator agents
    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    Over the short term (up to 4 years), patients with T2DM exposed to a DPP-4 inhibitor or GLP-1 receptor agonist were not at increased risk for MACE (or its component endpoints) compared with those who received comparator agents.
    1 context sentence
    Summary · context
    The National Institutes of Health Medline database was searched for pooled analyses, meta-analyses, and randomized controlled trials (RCTs) of DPP-4 inhibitors and GLP-1 receptor agonists that included CV endpoints.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.